The MarketWatch News Department was not involved in the creation of this content. -- Heart disease affects approximately 10 percent of dogs in their lifetime1 -- VETMEDIN(R) (pimobendan) from ...
How a new "breathalyzer" from the College of Veterinary Medicine could change the future of canine heart health.
Heart disease affects approximately 10 percent of dogs in their lifetime1 VETMEDIN® (pimobendan) from Boehringer Ingelheim is the only medication approved to treat preclinical mitral valve disease in ...
DULUTH, Ga., Jan. 19, 2026 /PRNewswire/ -- Boehringer Ingelheim, a global leader in animal health, today announced that the U.S. Food and Drug Administration (FDA) has approved VETMEDIN (pimobendan) ...
The FDA approved the first drug designed to delay congestive heart failure in dogs The medication targets dogs with early heart disease before symptoms develop Early treatment may improve lifespan and ...
Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: A view shows the U.S. Food and Drug Administration (FDA) headquarters in Silver Spring, Maryland August 14, 2012.
Jan 19 (Reuters) - Pharmaceutical company Boehringer Ingelheim said on Monday the U.S. Food and Drug Administration had approved its chewable tablet, as the first drug to delay congestive heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results